CU20140068A7 - Triazolopiridinas sustituidas - Google Patents

Triazolopiridinas sustituidas

Info

Publication number
CU20140068A7
CU20140068A7 CU2014000068A CU20140068A CU20140068A7 CU 20140068 A7 CU20140068 A7 CU 20140068A7 CU 2014000068 A CU2014000068 A CU 2014000068A CU 20140068 A CU20140068 A CU 20140068A CU 20140068 A7 CU20140068 A7 CU 20140068A7
Authority
CU
Cuba
Prior art keywords
compounds
substituted
triazolopiridins
preparing
formula
Prior art date
Application number
CU2014000068A
Other languages
English (en)
Inventor
Volker Schulze
Dirk Kosemund
Antje Margret Wengner
Gerhard Siemeister
Detlef Stöckigt
Michael Bruening
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20140068A7 publication Critical patent/CU20140068A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Compuestos de triazolopiridina sustituida de la fórmula general (I) EsESPACIO PARA FÓRMULA, donde R^1, R^2, R^3, R^4, R^5 tienen los valores que se definen en la descripción y en las reinvindicaciones. Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos intermediarios útiles para preparar dichos compuestos.
CU2014000068A 2011-12-12 2014-06-12 Triazolopiridinas sustituidas CU20140068A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12
PCT/EP2012/074978 WO2013087579A1 (en) 2011-12-12 2012-12-10 Substituted triazolopyridines and their use as ttk inhibitors

Publications (1)

Publication Number Publication Date
CU20140068A7 true CU20140068A7 (es) 2014-12-26

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000068A CU20140068A7 (es) 2011-12-12 2014-06-12 Triazolopiridinas sustituidas

Country Status (40)

Country Link
US (1) US9663510B2 (es)
EP (1) EP2791136B1 (es)
JP (1) JP6181664B2 (es)
KR (1) KR20140105552A (es)
CN (1) CN104114552B (es)
AP (1) AP4017A (es)
AR (1) AR089143A1 (es)
AU (1) AU2012350751B2 (es)
BR (1) BR112014014184A2 (es)
CA (1) CA2858683A1 (es)
CL (1) CL2014001546A1 (es)
CO (1) CO6980657A2 (es)
CR (1) CR20140275A (es)
CU (1) CU20140068A7 (es)
CY (1) CY1116958T1 (es)
DK (1) DK2791136T3 (es)
DO (1) DOP2014000133A (es)
EC (1) ECSP14004812A (es)
ES (1) ES2550677T3 (es)
GT (1) GT201400111A (es)
HK (1) HK1203200A1 (es)
HR (1) HRP20151103T1 (es)
HU (1) HUE025937T2 (es)
IL (1) IL232930A (es)
JO (1) JO3111B1 (es)
MA (1) MA35826B1 (es)
MX (1) MX2014007057A (es)
PE (1) PE20141597A1 (es)
PH (1) PH12014501319A1 (es)
PL (1) PL2791136T3 (es)
PT (1) PT2791136E (es)
RS (1) RS54288B1 (es)
RU (1) RU2632464C1 (es)
SG (1) SG11201402820SA (es)
SI (1) SI2791136T1 (es)
TN (1) TN2014000254A1 (es)
UA (1) UA112096C2 (es)
UY (1) UY34515A (es)
WO (1) WO2013087579A1 (es)
ZA (1) ZA201404031B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238979B2 (ja) * 2012-07-10 2017-11-29 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジンを調製する方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
SG11201509350RA (en) * 2013-06-11 2015-12-30 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
SG11201509858QA (en) * 2013-06-11 2015-12-30 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
WO2015176981A1 (en) * 2014-05-19 2015-11-26 Basf Se Fluorescent organic light emitting elements having high efficiency
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
WO2018077944A2 (en) 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR102668688B1 (ko) 2018-07-23 2024-05-24 삼성디스플레이 주식회사 유기 발광 소자
WO2020161257A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
KR20210059153A (ko) 2019-11-14 2021-05-25 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
CA2530679A1 (en) 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
AU2007291190A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EP2178868A1 (en) 2007-07-18 2010-04-28 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
CN103298814A (zh) 2007-08-23 2013-09-11 阿斯利康(瑞典)有限公司 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮
US8263595B2 (en) 2007-08-31 2012-09-11 Merck Serono Sa Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20100086492A (ko) 2007-11-27 2010-07-30 셀좀 리미티드 Ｐｉ3ｋ 억제제로서의 아미노 트리아졸
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
BRPI1008850A2 (pt) 2009-02-13 2016-03-15 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
PE20141351A1 (es) * 2011-04-21 2014-11-01 Bayer Ip Gmbh Triazolopiridinas

Also Published As

Publication number Publication date
WO2013087579A1 (en) 2013-06-20
AR089143A1 (es) 2014-07-30
HUE025937T2 (en) 2016-05-30
SI2791136T1 (sl) 2015-11-30
TN2014000254A1 (en) 2015-09-30
JP2015500308A (ja) 2015-01-05
AU2012350751B2 (en) 2017-07-06
EP2791136B1 (en) 2015-07-29
KR20140105552A (ko) 2014-09-01
HRP20151103T1 (en) 2015-11-20
PE20141597A1 (es) 2014-11-07
ZA201404031B (en) 2016-09-28
US9663510B2 (en) 2017-05-30
CA2858683A1 (en) 2013-06-20
PL2791136T3 (pl) 2015-12-31
UA112096C2 (uk) 2016-07-25
DOP2014000133A (es) 2014-07-31
ES2550677T3 (es) 2015-11-11
DK2791136T3 (en) 2015-10-26
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
CO6980657A2 (es) 2014-06-27
GT201400111A (es) 2015-11-30
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
EP2791136A1 (en) 2014-10-22
HK1203200A1 (en) 2015-10-23
UY34515A (es) 2013-07-31
US20150210683A1 (en) 2015-07-30
RS54288B1 (en) 2016-02-29
MA35826B1 (fr) 2014-12-01
NZ625815A (en) 2016-07-29
PH12014501319A1 (en) 2014-09-08
JO3111B1 (ar) 2017-09-20
IL232930A (en) 2016-07-31
PT2791136E (pt) 2015-11-04
CR20140275A (es) 2014-08-13
JP6181664B2 (ja) 2017-08-16
AP2014007731A0 (en) 2014-06-30
MX2014007057A (es) 2014-08-08
CN104114552B (zh) 2016-12-28
ECSP14004812A (es) 2015-11-30
CL2014001546A1 (es) 2014-10-24
CY1116958T1 (el) 2017-04-05
BR112014014184A2 (pt) 2017-06-13
AU2012350751A1 (en) 2014-06-26
IL232930A0 (en) 2014-08-03

Similar Documents

Publication Publication Date Title
CU20140068A7 (es) Triazolopiridinas sustituidas
CU20120171A7 (es) Triazolopiridinas sustituidas
ECSP13013011A (es) Triazolopiridinas
DOP2012000150A (es) Triazolopiridinas
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CR20160016A (es) Pirazolpiridinas sustituidas
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY34854A (es) Inhibidores del transporte de glucosa
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
CU20130141A7 (es) Triazolopiridinas
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos